Mechanism of Anti-Angiogenic and Renal Protective Activity of Balanites aegyptiaca Seeds Extract in Ehrlich Ascites Carcinoma-Bearing Mice
Abstract
Background: One of the animal angiogenesis with high inflammation and rapid growth is Ehrlich ascites carcinoma. Balanites aegyptiaca seeds extract (BASE), a new synthesized compound has antioxidant and antidiabetic activity. The purpose of this study was to evaluate anti-angiogenic activity of BASE in ehrlich ascites carcinoma (EAC)-bearing mice. Materials and Methods: BASE was prepared and characterized using instrumental analysis and spectral data. Furthermore, the IC50 of BASE against the renal carcinoma cell line (RCC-949) was calculated. Adult albino mice weighing 25±5 g was used to assess the anti-angiogenic activity of BASE (100 and 200 mg kg‾1 body weight) in EAC-bearing mice. Results: IC50 of BASE against the renal carcinoma cell line (RCC-949) was equal to 62.18 µg mL‾1. The daily oral administration of BASE at concentrations of 100 and 200 mg kg‾1 body weight for 30 days to EAC-bearing mice resulted in a significant improvement in tumor volume and tumor weight, urea, creatinine, uric acid, TNF-α, NOx, TBARs, GSH, CAT, SOD, GPx and VEGF-C gene expression in EAC-bearing mice. Furthermore, BASE almost normalized these effects in renal histoarchitecture. Conclusion: The BASE has anti-angiogenic activity in EAC-bearing mice.
Keywords:
Anticancer, balanites aegyptiaca, ehrlich ascites carcinoma, mice, renal carcinoma cell lineArticle Metrics
License
Copyright (c) 2021 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.